Hypersensitivity and cross-reactivity to cisplatin and analogues
A phase-II trial of the second-generation platinum analog 1,2-diaminocyclohexane (4-carboxyphalato) platinum (II) (DACCP) was performed in 33 patients with non-small cell lung cancer. The compound was studied because of its lack of cross resistance in vitro and decreased nephrotoxicity in both preclinical testing and in a phase-I trial. The starting dose was 640 mg/m2 IV every 3 weeks, with escalations to 720 mg/m2 in the absence of toxicity. Myelosuppression and nephrotoxicity were uncommon. Allergic reactions and neurotoxicity were seen in five and three patients, respectively. Of 28 patients evaluable for response, one partial remission of 3 months' duration was noted in a patient who had previously responded but subsequently progressed during cisplatin and vindesine medication. No responses were seen in 11 adequately treated patients who had received no prior therapy. DACCP has only minimal activity in non-small cell lung cancer. No further studies are planned in this disease.